drugset / Trial / NCT02561546
p53 Gene Therapy in Treatment of Diabetes Concurrent With Hepatocellular Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
An open-labeled phase II study to investigate preliminary efficacy using p53 gene therapy in treatment of diabetes concurrent with hepatocellular carcinoma (HCC).
Timeline
- Start
- 2015-12
- Primary completion
- 2017-10
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rAd-p53 | Unknown | — | Other |